SynthesisMolecular psychiatry2026
Long-Read sequencing in psychiatric omics: a systematic review of current evidence.
Synthesis in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe comprehensive elucidation of genomic relevance for mental disorder was, until recently, constrained by the limitations of microarrays or short-read sequencing (SRS). Long-read sequencing (LRS) provides access to complex classes of genetic variation and genomic architecture that are largely obscured in SRS approaches, making it a powerful tool for uncovering missing heritability and mechanistic insights in mental disorders.
objectiveWe synthesize current evidence on the application of LRS technologies across genomic, transcriptomic, and methylomic studies of mental disorders. The systematic review was conducted in accordance with PRISMA guidelines. RESULTS AND DISCUSSION: The literature search yielded 2,166 articles, and 14 were included in the review after applying inclusion and exclusion criteria. From a genomic perspective, LRS consistently outperformed SRS, increasing structural variant (SV) and de novo mutation (DNM) detection, particularly resolving medium-sized SVs and large inversions in repetitive regions. Transcriptomic studies established LRS as essential for achieving full-length transcript resolution, uncovering substantial novel isoform diversity and widespread alternative splicing events in the human neocortex. Crucially, LRS demonstrated that psychiatric risk is often conferred by dysregulated alternative splicing leading to isoform-specific imbalances, rather than altered total gene expression. At the epigenomic level, LRS enabled the haplotype-specific mapping of Allele-Specific Methylation within genome-wide significant loci, linking genetic risk to epigenetic dysregulation. Overall, LRS represents a significant technological advancement, providing the high-resolution molecular detail necessary to begin characterizing the complex relationships between genetic variation, splicing dynamics, and epigenetic modifications, thereby helping to contextualize psychiatric risk associations for future translational research.
Identifiers
42791269What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.